Zero-Contrast Left Atrial Appendage Occlusion Using a Hybrid Echocardiography-Fluoroscopy Technique Without Iodinated Contrast.

Autor: Blusztein DI; Division of Cardiology, Columbia University Irving Medical Center, New York, New York. Electronic address: davidblusztein@gmail.com., Gogia S; Division of Cardiology, Columbia University Irving Medical Center, New York, New York., Hahn RT; Division of Cardiology, Columbia University Irving Medical Center, New York, New York., Sommer RJ; Division of Cardiology, Columbia University Irving Medical Center, New York, New York., Ng V; Division of Cardiology, Columbia University Irving Medical Center, New York, New York., Forman J; Division of Cardiology, Columbia University Irving Medical Center, New York, New York., Lebehn M; Division of Cardiology, Columbia University Irving Medical Center, New York, New York., Ranard L; Division of Cardiology, Columbia University Irving Medical Center, New York, New York., Vahl TP; Division of Cardiology, Columbia University Irving Medical Center, New York, New York.
Jazyk: angličtina
Zdroj: The American journal of cardiology [Am J Cardiol] 2023 Jul 01; Vol. 198, pp. 53-55. Date of Electronic Publication: 2023 May 16.
DOI: 10.1016/j.amjcard.2023.04.027
Abstrakt: Contrast exposure during left atrial appendage occlusion may be harmful in those with chronic kidney disease or allergy. This single-center registry (n = 31) demonstrates the feasibility and safety of zero-contrast percutaneous left atrial appendage occlusion using echocardiography, fluoroscopy, and fusion imaging, with 100% procedural success and no device complications at 45 days.
Competing Interests: Declaration of Competing Interest Dr. Hahn reports speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; and has Equity with Navigate. Dr. Sommer is a trainer for Boston Scientific's WATCHMAN device and is an investigator for Boston Scientifics OPTION (Comparison of Anticoagulation With Left Atrial Appendage Closure After atrial fibrillation ablation) and CHAMPION-AF (WATCHMAN FLX vs NOAC for Embolic Protection in the Management of Patients With nonvalvular atrial fibrillation) trials; is also the National Principal Investigator on the ASSURED ASD trial (Safety and Efficacy Study of transcatheter Closure of ostium secundum ASDs) of WL Gore, and the upcoming Gore RELIEF Clinical Study for the migraine-PFO connection. Dr. Ranard reports institutional funding to Columbia University Medical Center from Boston Scientific. Dr. Vahl reports institutional funding to Columbia University Irving Medical Center from Boston Scientific, Edwards Lifesciences, JenaValve, Medtronic, and Siemens Healthineers and has received consulting fees from Abbott Vascular, Boston Scientific, InnovHeart, and 4C Medical. The remaining authors have no conflicts of interest to declare.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: